Media & news

Danaher controls more than 98% of Nobel Biocare and started squeeze out procedure; Nobel Biocare applied for delisting

Nobel Biocare Holding AG has been informed that Danaher Corporation today filed a petition with the Commercial Court of the Canton of Zurich for the annulation (Kraftloserklärung) of the remaining publicly held registered shares of Nobel Biocare against payment of the offer price that had been offered and paid by Danaher in its public tender offer for all publicly held registered shares of Nobel Biocare. 

Also, Nobel Biocare today filed petitions with SIX Swiss Exchange for the de-listing (Dekotierung) of the registered shares of Nobel Biocare from SIX Swiss Exchange and for exemptions from certain obligations under the Listing Rules of SIX Swiss Exchange, including in particular from certain publicity obligations.Danaher's intentions with respect to these petitions had been disclosed and announced in its public tender offer documents. 

Contact information:

Süha Demokan

Investor & Corporate Relations

Tel: +41 43 211 42 30, +41 79 430 81 46

Nobel Biocare is a world leader in the field of innovative implant-based dental restorations. The company’s portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, Brånemark System® and NobelReplace®), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), diagnostics, treatment planning and guided surgery solutions (NobelClinician® and DTX Studio™) and biomaterials (creos). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland. Production takes place at six sites located in the United States, Sweden, Japan and Israel. Products and services are available in over 80 countries through subsidiaries and distributors.